Session Type: Poster Session (Monday)
Session Time: 9:00AM-11:00AM
Background/Purpose: Systemic inflammation may influence cardio-metabolic profiles and increases the risk of CV disorders in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients (pts)1. Treatment with tumor necrosis factor (TNF) and Janus Kinase inhibitors have reported increased total cholesterol (TC) and triglycerides (TG) despite reduction in inflammation2,3. Here, we present the long-term effect of secukinumab (SEC), a fully human monoclonal antibody that directly inhibits interleukin (IL) -17A, on key cardio-metabolic parameters in AS and PsA pts from a pooled analysis of phase 3 clinical trials, through 156 weeks (wks).
Methods: This post hoc analysis pooled data from MEASURE 1−4 studies in AS (N=892) and FUTURE 2−5 studies in PsA (N=2049), and included pts treated with SEC 150 mg and SEC 300/150 mg, respectively, or placebo (PBO; Wk 16 data). Serum glucose, body mass index (BMI), TG, TC/high-density lipoprotein cholesterol (TC/HDL-C), systolic/diastolic blood pressure (BP), C-reactive protein (CRP) levels were assessed at baseline (BL), Wks 16, 104 and 156 in overall population and in sub-groups by prior anti-TNF therapy and concomitant methotrexate (MTX) usage.
Results: BL characteristics were generally comparable across SEC and PBO groups in both disease cohorts. Serum glucose, systolic/diastolic BP, BMI, and lipid (TG, TC/HDL) levels were minimally altered in SEC treated pts with AS and PsA through Wk 156 (Table); mean change from BL in AS: TG (mmol/L) = 0.1−0.2, TC/HDL-C = ±0.2, glucose (mmol/L) = 0.08−0.2, BMI (kg/m2) = 0.08−0.9, BP (mmHg) = ±0.2/±0.9 (systolic/diastolic) and mean change from BL in PsA: TG (mmol/L) = 0.003−0.2, TC/HDL-C = ±0.2, glucose (mmol/L) = ±0.3, BMI (kg/m2) = 0.1−1.7, BP (mmHg) = ±4.0/±1.0 (systolic/diastolic). CRP reductions were observed through Wk 156 (Table). Results were broadly similar in sub-groups by prior anti-TNF therapy and concomitant MTX use through Wk 156.
Conclusion: Secukinumab was associated with minimal changes in cardio-metabolic parameters over 3 years in patients with ankylosing spondylitis and psoriatic arthritis. These findings suggest that anti-IL-17 therapy may be an option in patients with cardio-metabolic risk factors, however, further research is needed.
- Papagoras C, et al. Joint Bone Spine. 2014;81:57-63
- Wolk R, et al. J Clin Lipidol. 2017;11:1243-56
- Agca R, et al. J Rheumatol. 2017; 44(9):1362-8
To cite this abstract in AMA style:McInnes I, Gladman D, Deodhar A, Miceli-Richard C, Nash P, Sattar N, Mehta N, Asquith D, Wang J, Richards H, Pricop L, Shete A. Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/effect-of-long-term-treatment-with-secukinumab-on-cardio-metabolic-profile-in-patients-with-active-ankylosing-spondylitis-and-psoriatic-arthritis-pooled-3-year-analysis/. Accessed October 19, 2021.
« Back to 2019 ACR/ARP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-long-term-treatment-with-secukinumab-on-cardio-metabolic-profile-in-patients-with-active-ankylosing-spondylitis-and-psoriatic-arthritis-pooled-3-year-analysis/